ResearcherAsahikawa Medical UniversityActive in the last 2 years
Tetsuhiro Okada
Matched on OpenAlex author ID A5065354515. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 7
- Extracellular vesicle-encapsulated microRNA-425 promotes tumor development and serves as a biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-026-02382-9↗
- Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway. Co-author DOI 10.1007/s00535-021-01846-4↗
- Prognostic significance of skeletal muscle decrease in unresectable pancreatic cancer: Survival analysis using the Weibull exponential distribution model. Co-author DOI 10.1016/j.pan.2021.03.002↗
- Resection for pancreatic cancer metastases contributes to survival: A case report with sequential tumor genotype profiling during the long-term postoperative c… Co-author DOI 10.1097/md.0000000000020564↗
- Genetic Tracing of Clonal Expansion and Progression of Pancreatic Ductal Adenocarcinoma: A Case Report and Multi-Region Sequencing Analysis. Co-author DOI 10.3389/fonc.2020.00728↗
- Genetic analysis of postoperative recurrence of pancreatic cancer potentially owing to needle tract seeding during EUS-FNB. Co-author DOI 10.1055/a-1034-7700↗
- Utility of "liquid biopsy" using pancreatic juice for early detection of pancreatic cancer. Co-author DOI 10.1055/a-0721-1747↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yusuke Mizukami · 7 shared papers, 2018–2026 · strength 0.77
- Paper Extracellular vesicle-encapsulated microRNA-425 promotes tumor development and serves as a biomarker for pancreatic duc… DOI 10.1007/s00535-026-02382-9↗
- Paper Prognostic significance of skeletal muscle decrease in unresectable pancreatic cancer: Survival analysis using the Weib… DOI 10.1016/j.pan.2021.03.002↗
- Paper Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway. DOI 10.1007/s00535-021-01846-4↗
- Toshikatsu Okumura · 7 shared papers, 2018–2026 · strength 0.77
- Paper Extracellular vesicle-encapsulated microRNA-425 promotes tumor development and serves as a biomarker for pancreatic duc… DOI 10.1007/s00535-026-02382-9↗
- Paper Prognostic significance of skeletal muscle decrease in unresectable pancreatic cancer: Survival analysis using the Weib… DOI 10.1016/j.pan.2021.03.002↗
- Paper Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway. DOI 10.1007/s00535-021-01846-4↗
- Hidemasa Kawabata · 6 shared papers, 2018–2026 · strength 0.68
- Paper Extracellular vesicle-encapsulated microRNA-425 promotes tumor development and serves as a biomarker for pancreatic duc… DOI 10.1007/s00535-026-02382-9↗
- Paper Prognostic significance of skeletal muscle decrease in unresectable pancreatic cancer: Survival analysis using the Weib… DOI 10.1016/j.pan.2021.03.002↗
- Paper Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway. DOI 10.1007/s00535-021-01846-4↗
- Mikihiro Fujiya · 5 shared papers, 2019–2026 · strength 0.61
- Paper Extracellular vesicle-encapsulated microRNA-425 promotes tumor development and serves as a biomarker for pancreatic duc… DOI 10.1007/s00535-026-02382-9↗
- Paper Prognostic significance of skeletal muscle decrease in unresectable pancreatic cancer: Survival analysis using the Weib… DOI 10.1016/j.pan.2021.03.002↗
- Paper Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway. DOI 10.1007/s00535-021-01846-4↗
- Hiroki Sato · 5 shared papers, 2018–2022 · strength 0.46
- Paper Prognostic significance of skeletal muscle decrease in unresectable pancreatic cancer: Survival analysis using the Weib… DOI 10.1016/j.pan.2021.03.002↗
- Paper Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway. DOI 10.1007/s00535-021-01846-4↗
- Paper Resection for pancreatic cancer metastases contributes to survival: A case report with sequential tumor genotype profil… DOI 10.1097/md.0000000000020564↗
- Junpei Sasajima · 5 shared papers, 2018–2021 · strength 0.44
- Paper Prognostic significance of skeletal muscle decrease in unresectable pancreatic cancer: Survival analysis using the Weib… DOI 10.1016/j.pan.2021.03.002↗
- Paper Resection for pancreatic cancer metastases contributes to survival: A case report with sequential tumor genotype profil… DOI 10.1097/md.0000000000020564↗
- Paper Genetic Tracing of Clonal Expansion and Progression of Pancreatic Ductal Adenocarcinoma: A Case Report and Multi-Region… DOI 10.3389/fonc.2020.00728↗
- Kenji Takahashi · 2 shared papers, 2022–2026 · strength 0.33
- Paper Extracellular vesicle-encapsulated microRNA-425 promotes tumor development and serves as a biomarker for pancreatic duc… DOI 10.1007/s00535-026-02382-9↗
- Paper Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway. DOI 10.1007/s00535-021-01846-4↗
- Yuko Omori · 3 shared papers, 2018–2020 · strength 0.23
- Paper Genetic Tracing of Clonal Expansion and Progression of Pancreatic Ductal Adenocarcinoma: A Case Report and Multi-Region… DOI 10.3389/fonc.2020.00728↗
- Paper Genetic analysis of postoperative recurrence of pancreatic cancer potentially owing to needle tract seeding during EUS-… DOI 10.1055/a-1034-7700↗
- Paper Utility of "liquid biopsy" using pancreatic juice for early detection of pancreatic cancer. DOI 10.1055/a-0721-1747↗
- Yohei Kitano · 1 shared paper, 2026 · strength 0.22
- Kazuya Koyama · 1 shared paper, 2026 · strength 0.22
- Hiroaki Konishi · 1 shared paper, 2022 · strength 0.11
- Andrew Scott Liss · 1 shared paper, 2022 · strength 0.11
- Shion Tachibana · 1 shared paper, 2020 · strength 0.09
- Shinya Tanaka · 1 shared paper, 2020 · strength 0.09
- Toru Furukawa · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.